Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line

Nature Reviews Neurology volume 12, pages 675–676 (2016)Cite this article

Subjects

New therapies are much needed for Duchenne muscular dystrophy. Recent data from a phase II clinical trial has led to accelerated FDA approval of the exon-skipping drug eteplirsen. This approval is provisional, pending results of an ongoing phase III clinical trial, and came after much debate.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77–93 (2010).

    Article  Google Scholar 

  2. Wilton, S. D., Dye, D. E., Blechynden, L. M. & Laing, N. G. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul. Disord. 7, 329–335 (1997).

    Article  CAS  Google Scholar 

  3. Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637–647 (2013).

    Article  CAS  Google Scholar 

  4. Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257–271 (2016).

    Article  CAS  Google Scholar 

  5. Voit, T. et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 13, 987–996 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author would like to thank Kyla Dunn for critical reading and editing.

Author information

Authors and Affiliations

  1. Division of Neurology and Program for Genetics and Genome Biology, Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8, Ontario, Canada

    James J. Dowling

Authors
  1. James J. Dowling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James J. Dowling.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dowling, J. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat Rev Neurol 12, 675–676 (2016). https://doi.org/10.1038/nrneurol.2016.180

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.180

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research